Mitapro-30 Tablet

About Mitapro-30 Tablet

Mitapro-30 is a tablet medicine used to treat major depressive disorder. Its active ingredient is mirtazapine, and it works in the brain to support mood. It belongs to a group of medicines called atypical antidepressants, and a doctor decides whether it suits you.

There are 20 brands of Mirtazapine listed in Bangladesh. The lowest listed price is Rapine 7.5 Tablet at ৳ 6 per unit.

What is Mitapro-30 Tablet?

Mitapro-30 30 mg Tablet contains mirtazapine, an atypical antidepressant. It is prescribed for major depressive disorder. The exact way mirtazapine lifts mood is not fully understood, but it is thought to increase certain chemical messenger activity in the central nervous system by blocking particular receptors. It also has a sedative effect that some people notice. Because it can make you drowsy and affect alertness, your doctor will consider this when prescribing it and will decide the dose and how long you take it.

Uses of Mitapro-30

Mitapro-30 is used to treat major depressive disorder in adults. It is not a quick fix and is taken as part of a plan your doctor sets up. Depression can affect sleep, appetite, energy and interest in daily life, and treatment aims to ease these symptoms over time. Only a qualified doctor can confirm whether this medicine is appropriate for your situation.

How to use Mitapro-30

Take Mitapro-30 exactly as your doctor tells you. The doctor decides the dose and how long you take it, and may adjust it over time as your response is reviewed. Swallow the tablet as directed. Do not stop it suddenly or change the dose on your own, because your doctor needs to manage any change carefully. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Mitapro-30

Common side effects include dizziness, drowsiness, dry mouth, increased appetite and weight gain. Some people notice anxiety, agitation, restlessness or unusual changes in behaviour, especially early in treatment or when the dose is adjusted. Contact your doctor promptly if you feel worse, have thoughts of harming yourself, or notice severe or troubling symptoms. Do not drive or operate machinery if you feel drowsy.

Safety and precautions

Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding, because this medicine needs medical advice in these situations. Do not take Mitapro-30 with a monoamine oxidase inhibitor, and tell your doctor about all other medicines you take, including those for mood, pain or infections. Avoid alcohol and diazepam while taking it. People with a known allergy to mirtazapine should not use it. Because it can cause drowsiness and affect judgment, be careful with driving and skilled tasks.

Frequently asked questions

What is Mitapro-30 used for and what kind of medicine is it?

Mitapro-30 is an atypical antidepressant containing mirtazapine. It is used to treat major depressive disorder in adults. It is a prescription medicine, so only a doctor can decide whether it is right for you and how it should be taken.

Is Mitapro-30 safe during pregnancy or breastfeeding?

Pregnancy and breastfeeding need extra care with this medicine. Tell your doctor if you are pregnant, might become pregnant, or are breastfeeding, so they can advise you. Do not start or stop it on your own; your doctor will weigh the benefits and risks for your situation.

What side effects should I watch for, and when should I call the doctor?

Watch for dizziness, drowsiness, dry mouth, increased appetite and weight gain. Call your doctor if you feel worse, notice restlessness, agitation or unusual behaviour changes, or have thoughts of harming yourself. Seek help promptly for any severe or worrying symptom.

Can I stop taking Mitapro-30 on my own?

No. Do not stop suddenly or change the dose without your doctor's advice. Your doctor will decide how long you take it and how to make any changes safely. If you have concerns about your treatment, talk to your doctor or pharmacist first.

Indications

Mirtazapine Tablets are indicated for the treatment of major depressive disorder (MDD).

Pharmacology

Pharmacodynamics: The mechanism of action of Mirtazapine as with other drugs effective in the treatment of major depressive disorder is unknown. Evidence gathered in preclinical studies suggests that Mirtazapine enhances central noradrenergic and serotonergic activity. These studies have shown that Mirtazapine acts as an antagonist at central presynaptic α2-adrenergic inhibitory autoreceptors and heteroreceptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. Mirtazapine is a potent antagonist of 5- HT2 and 5-HT3 receptors. Mirtazapine has no significant affinity for the 5-HT1A and 5-HT1B receptors. Mirtazapine is a potent antagonist of histamine (H1) receptors, a property that may explain its prominent sedative effects. Mirtazapine is a moderate peripheral α1-adrenergic antagonist, a property that may explain the occasional orthostatic hypotension reported in association with its use. Mirtazapine is a moderate antagonist at muscarinic receptors, a property that may explain the relatively low incidence of anticholinergic side effects associated with its use.

Pharmacokinetics: After oral administration of Mirtazapine tablets, the active constituent mirtazapine is rapidly and well-absorbed, reaching peak plasma levels after about 2 hours. Binding of mirtazapine to plasma proteins is approximately 85%. The mean half-life of elimination is 20-40 hours; (26 hours in males, 37 hours in females). The half-life of elimination is sufficient to justify once-a-day dosing. Mirtazapine displays linear pharmacokinetics within the recommended dose range. Mirtazapine is extensively metabolized and eliminated via the urine and faeces four days. Major pathways of biotransformation are demethylation and oxidation followed by conjugation.

Dosage & Administration

Adult dose: The recommended starting dose for Mirtazapine tablets is 15 mg/day, administered in a single dose, preferably in the evening or prior to sleep. The effective dose range was generally 15 to 45 mg/day and the patients not responding to the initial 15 mg dose may benefit from dose increases up to a 30 mg to maximum of 45 mg/day. Mirtazapine has an elimination half-life of approximately 20 to 40 hours; therefore, dose changes should be made at intervals of less than 1 to 2 weeks in order to allow sufficient time for the therapeutic response to a given dose.

Use in children: Use in children are not recommended to Mirtazapine.

Missed Dose: If anyone misses a dose of mirtazapine, take it as soon as remember unless it is close to when the next dose is due. If anyone missed a dose of medication and it is close to the time of next dose, skip the missed dose and should take next dose at the regularly scheduled time. One should not take double or more than prescribed dose.

Interaction

Mirtazapine has clinically significant drug-drug interactions with Monoamine Oxidase Inhibitors (MAOI) & other serotonergic drugs such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St. John's wort. Mirtazapine may interrupt the metabolism or activity of Carbamazepine, Phenytoin or Cimetidine. Patient should avoid Alcohol & Diazepam while taking Mirtazapine.

Contraindications

Hypersensitivity: Mirtazapine is contraindicated in patients with a known hypersensitivity to Mirtazapine or to any of the excipients.

Monoamine Oxidase Inhibitors: The concomitant use of Mirtazapine and a monoamine oxidase (MAO) inhibitor is contraindicated. Mirtazapine should not be used within 14 days of initiating or discontinuing therapy with a monoamine oxidase inhibitor (MAOI).

Side Effects

The most common side effects of Mirtazapine are dizziness, drowsiness, dry mouth, increased appetite, weight gain etc.

Pregnancy & Lactation

Pregnancy Category-C. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during Mirtazapine therapy. Patients should be advised to notify their physician if they are breastfeeding an infant.

Precautions & Warnings

Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Patients who are to receive Mirtazapine should be warned about the risk of developing agranulocytosis. Mirtazapine may impair judgment, thinking, and particularly, motor skills, because of its prominent sedative effect. Clinically significant ALT (SGPT) elevations (≥3 times the upper limit of the normal range) may occur.

Storage Conditions

Keep away from light and moisture. Store below 30º C. Keep all medicine out of the reach of children.

Alternative brands of Mirtazapine

Other brands with the same generic name, cheapest first.

See all 20 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.